High-Frequency Deep Brain Stimulation of the Substantia Nigra Pars Reticulata Facilitates Extinction and Prevents Reinstatement of Methamphetamine-Induced Conditioned Place Preference.
deep brain stimulation
extinction
methamphetamine
relapse
substantia nigra pars reticulata
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
06
05
2021
accepted:
10
06
2021
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Persistent and stable drug memories lead to a high rate of relapse among addicts. A number of studies have found that intervention in addiction-related memories can effectively prevent relapse. Deep brain stimulation (DBS) exhibits distinct therapeutic effects and advantages in the treatment of neurological and psychiatric disorders. In addition, recent studies have also found that the substantia nigra pars reticulata (SNr) could serve as a promising target in the treatment of addiction. Therefore, the present study aimed to investigate the effect of DBS of the SNr on the reinstatement of drug-seeking behaviors. Electrodes were bilaterally implanted into the SNr of rats before training of methamphetamine-induced conditioned place preference (CPP). High-frequency (HF) or low-frequency (LF) DBS was then applied to the SNr during the drug-free extinction sessions. We found that HF DBS, during the extinction sessions, facilitated extinction of methamphetamine-induced CPP and prevented drug-primed reinstatement, while LF DBS impaired the extinction. Both HF and LF DBS did not affect locomotor activity or induce anxiety-like behaviors of rats. Finally, HF DBS had no effect on the formation of methamphetamine-induced CPP. In conclusion, our results suggest that HF DBS of the SNr could promote extinction and prevent reinstatement of methamphetamine-induced CPP, and the SNr may serve as a potential therapeutic target in the treatment of drug addiction.
Identifiants
pubmed: 34276387
doi: 10.3389/fphar.2021.705813
pii: 705813
pmc: PMC8277946
doi:
Types de publication
Journal Article
Langues
eng
Pagination
705813Informations de copyright
Copyright © 2021 Zhang, Meng, Chen, Chen, Huang, Zhang, Liang, Ding, Xue, Chen, Shi and Shi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Ann Neurol. 2018 Feb;83(2):352-362
pubmed: 29369401
Prog Brain Res. 2007;160:151-72
pubmed: 17499113
Addict Biol. 2018 Mar;23(2):699-712
pubmed: 28661034
Lancet Psychiatry. 2017 Nov;4(11):839-849
pubmed: 28988904
Int J Neuropsychopharmacol. 2014 Oct 31;18(5):
pubmed: 25522412
Nat Rev Neurosci. 2001 Oct;2(10):695-703
pubmed: 11584307
Cell. 2015 Aug 13;162(4):712-25
pubmed: 26276628
Neurosci Biobehav Rev. 2012 Apr;36(4):1119-39
pubmed: 22285426
Eur J Neurosci. 2019 Aug;50(3):2503-2512
pubmed: 30113098
Nat Commun. 2020 Feb 17;11(1):923
pubmed: 32066723
Science. 2020 Jan 24;367(6476):440-445
pubmed: 31974254
J Physiol. 2012 May 15;590(10):2427-42
pubmed: 22393250
J Neurosurg. 2017 Apr;126(4):1339-1350
pubmed: 27392268
Neuropsychopharmacology. 2015 Aug;40(9):2146-56
pubmed: 25722116
J Neurosci. 2014 May 7;34(19):6647-58
pubmed: 24806690
J Clin Invest. 2019 Jun 13;129(9):3833-3838
pubmed: 31194696
Neuropsychopharmacology. 2014 Apr;39(5):1169-77
pubmed: 24232172
Sleep. 2021 Jan 21;44(1):
pubmed: 32808987
Addict Biol. 2020 Jul;25(4):e12780
pubmed: 31210397
Biol Psychiatry. 2020 Jun 1;87(11):944-953
pubmed: 31928716
Neurosurg Focus. 2018 Aug;45(2):E11
pubmed: 30064320
Neuron. 2016 Jun 1;90(5):1071-1085
pubmed: 27210555
J Neurosci. 2020 Nov 11;40(46):8853-8869
pubmed: 33046548
Behav Brain Res. 2015 Mar 15;281:125-30
pubmed: 25529183
Nat Neurosci. 2013 Apr;16(4):386-7
pubmed: 23434914
Sci Transl Med. 2020 Dec 2;12(572):
pubmed: 33268512
Brain Stimul. 2019 Jan - Feb;12(1):175-183
pubmed: 30245163
Annu Rev Neurosci. 2006;29:565-98
pubmed: 16776597
Neuropharmacology. 2020 Sep 1;174:108136
pubmed: 32474027
Elife. 2020 Sep 07;9:
pubmed: 32894224
Addiction. 2002 Feb;97(2):155-67
pubmed: 11860387
Elife. 2019 Mar 06;8:
pubmed: 30839276
N Engl J Med. 2000 Feb 17;342(7):461-8
pubmed: 10675426
Lancet. 2013 Apr 20;381(9875):1361-1370
pubmed: 23473846
Mov Disord. 2018 Sep;33(9):1423-1431
pubmed: 29756399
Nat Neurosci. 2014 Apr;17(4):577-85
pubmed: 24584054
Lancet Psychiatry. 2017 Apr;4(4):285-294
pubmed: 28238701
J Neurosurg. 2007 Jul;107(1):29-36
pubmed: 17639870
Neuroimage. 2017 Feb 1;146:1050-1061
pubmed: 27825979
Science. 2012 Apr 13;336(6078):167-8
pubmed: 22499932
N Engl J Med. 2012 Oct 18;367(16):1529-38
pubmed: 23075179
Neuron. 2010 Jun 24;66(6):896-907
pubmed: 20620875
Nat Commun. 2015 Jul 14;6:7675
pubmed: 26169171
Neuron. 2011 Oct 20;72(2):370-84
pubmed: 22017994
J Neurosci. 2011 Jan 26;31(4):1183-92
pubmed: 21273403
Ann Neurol. 2015 Apr;77(4):710-9
pubmed: 25627340
Dev Med Child Neurol. 2019 Jan;61(1):49-56
pubmed: 30320439
Front Neurosci. 2018 Aug 21;12:387
pubmed: 30186100
Science. 2015 Feb 6;347(6222):659-64
pubmed: 25657248
Nat Rev Neurosci. 2007 Aug;8(8):623-35
pubmed: 17637800
Mol Psychiatry. 2021 Jan;26(1):60-65
pubmed: 33144712
J Neurosci. 2017 Sep 13;37(37):8938-8951
pubmed: 28821652
Ann N Y Acad Sci. 2013 Apr;1282:119-28
pubmed: 23227826
Neuropsychopharmacology. 2011 Sep;36(10):1972-81
pubmed: 21633338
Biol Psychiatry. 2016 Nov 1;80(9):682-690
pubmed: 27449798
Mol Psychiatry. 2012 Jun;17(6):572-83
pubmed: 21931318
Parkinsonism Relat Disord. 2019 Mar;60:153-157
pubmed: 30241951
Nat Neurosci. 2014 Feb;17(2):254-61
pubmed: 24413699
Neuroscience. 2013 Oct 22;251:2-20
pubmed: 23867772
J Neurosci. 2008 Aug 27;28(35):8735-9
pubmed: 18753374
Proc Natl Acad Sci U S A. 2019 Dec 16;:
pubmed: 31843937
Neurotoxicology. 2020 Mar;77:20-28
pubmed: 31812708
Nat Rev Neurosci. 2007 Nov;8(11):844-58
pubmed: 17948030
Science. 2012 Apr 13;336(6078):241-5
pubmed: 22499948
Am J Psychiatry. 2019 Nov 1;176(11):949-956
pubmed: 31581800
Front Mol Neurosci. 2019 Jul 02;12:157
pubmed: 31312119
JAMA Neurol. 2013 Feb;70(2):163-71
pubmed: 23407652
Addict Biol. 2019 Mar;24(2):251-264
pubmed: 29314464
Brain. 2009 Jan;132(Pt 1):172-84
pubmed: 19001482
J Neurosci. 2013 Sep 4;33(36):14446-54
pubmed: 24005296
Am J Psychiatry. 2011 May;168(5):502-10
pubmed: 21285143
Am J Psychiatry. 2020 Nov 1;177(11):1038-1047
pubmed: 32854531